Davis Polk advised the joint book-running managers in connection with a $36 million SEC-registered common stock offering by Aeglea BioTherapeutics, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “AGLE.” 

Based in Austin, Texas, Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Emily Roberts and Ali DeGolia. The tax team included partner Rachel D. Kleinberg. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post